Teclistamab in Relapsed or Refractory Multiple MyelomaPhilippe Moreau, Saad Z. Usmani, Rian Van Rampelbergh et al.|New England Journal of Medicine|2022Cited by 1.2k
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myelomaThomas G Martin, Cesar Rodriguez, María‐Victoria Mateos et al.|Cancer|2023Cited by 66
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortés‐Selva, Raluca Verona, Tatiana Perova et al.|Blood|2024Cited by 60
Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1Diana Cortés‐Selva, Raluca Verona, Tineke Casneuf et al.|Blood|2022Cited by 46
Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Liviawati S. Wu et al.|Targeted Oncology|2023Cited by 46